ES2194677T3 - Suspensiones de trovafloxacina de administracion por via oral. - Google Patents

Suspensiones de trovafloxacina de administracion por via oral.

Info

Publication number
ES2194677T3
ES2194677T3 ES00304550T ES00304550T ES2194677T3 ES 2194677 T3 ES2194677 T3 ES 2194677T3 ES 00304550 T ES00304550 T ES 00304550T ES 00304550 T ES00304550 T ES 00304550T ES 2194677 T3 ES2194677 T3 ES 2194677T3
Authority
ES
Spain
Prior art keywords
suspensions
crystals
trovafloxacine
administration via
via oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00304550T
Other languages
English (en)
Inventor
Douglas John Allen
Sojka Sonja Sekulic
Daniel Ray Arenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2194677T3 publication Critical patent/ES2194677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

Un cristal de ión bipolar de trovafloxacina de la **fórmula** con una forma de tablillas de seis caras, que presenta el siguiente patrón de difracción de rayos X de torta húmeda. Nº de 1 2 3 4 5 6 7 8 9 pico 2q(°) 6, 2 8, 6 11, 12, 12, 8 16, 16, 8 18, 19, 5 Cu 8 4 1 6 espacio 14, 3 10, 7, 5 7, 1 6, 9 5, 5 5, 3 4, 8 4, 5 d 0 Nº de 10 11 12 13 14 15 16 17 18 pico 2q(°) 20, 1 22, 23, 26, 28, 3 29, 37, 7 39, Cu 6 7 7 9 0 espacio 4, 4 4, 1 3, 8 3, 3 3, 2 3, 0 2, 4 2, 3 d
ES00304550T 1999-06-04 2000-05-30 Suspensiones de trovafloxacina de administracion por via oral. Expired - Lifetime ES2194677T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13746399P 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
ES2194677T3 true ES2194677T3 (es) 2003-12-01

Family

ID=22477550

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00304550T Expired - Lifetime ES2194677T3 (es) 1999-06-04 2000-05-30 Suspensiones de trovafloxacina de administracion por via oral.

Country Status (10)

Country Link
US (1) US6239141B1 (es)
EP (1) EP1057828B1 (es)
JP (1) JP3465820B2 (es)
AT (1) ATE234835T1 (es)
BR (1) BR0002577A (es)
CA (1) CA2311112A1 (es)
DE (1) DE60001687T2 (es)
DK (1) DK1057828T3 (es)
ES (1) ES2194677T3 (es)
PT (1) PT1057828E (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
WO2002072102A1 (en) * 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
JP2005502628A (ja) * 2001-07-10 2005-01-27 ファルマシア・アンド・アップジョン・カンパニー 結晶性チアジンオキサゾリジノン
DK3168218T3 (en) * 2001-08-15 2019-01-14 Pharmacia & Upjohn Co Llc Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
US8367098B2 (en) * 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5266559A (en) 1989-10-27 1993-11-30 Firmenich S.A. Use of unsaturated macrocyclic lactones as perfuming ingredients
US5391763A (en) 1990-07-11 1995-02-21 Pfizer Inc. 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids
TW271400B (es) 1992-07-30 1996-03-01 Pfizer
JP3145715B2 (ja) 1995-06-06 2001-03-12 ファイザー・インコーポレーテッド 無水７−（［１α，５α，６α］−６−アミノ−３−アザビシクロ［３．１．０］ヘキサ−３−イル）−６−フルオロ−１−（２，４−ジフルオロフェニル）−１，４−ジヒドロ−４−オキソ−１，８−ナフチリディン−３−カルボン酸メタンスルホン酸塩の新規な結晶形態
NZ312199A (en) 1995-08-29 1999-06-29 Pfizer Zwitterionic forms of trovafloxacin
EP0847400B1 (en) * 1995-08-29 2001-11-14 Pfizer Inc. Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin
US6114531A (en) * 1998-07-28 2000-09-05 Pfizer Inc. Process for preparing quinolone and naphthyridone carboxylic acids

Also Published As

Publication number Publication date
DK1057828T3 (da) 2003-07-14
PT1057828E (pt) 2003-07-31
BR0002577A (pt) 2001-01-02
DE60001687T2 (de) 2003-12-18
EP1057828A2 (en) 2000-12-06
JP3465820B2 (ja) 2003-11-10
CA2311112A1 (en) 2000-12-04
JP2000344770A (ja) 2000-12-12
DE60001687D1 (de) 2003-04-24
US6239141B1 (en) 2001-05-29
EP1057828A3 (en) 2001-05-16
EP1057828B1 (en) 2003-03-19
ATE234835T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
BR0002577A (pt) Suspensões orais de trovafloxacina
IL165715A0 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TWI232219B (en) Compounds containing cyclohexane group, process for preparing them and pharmaceutical composition containing them
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
EA199901014A1 (ru) C-4"-замещенные макролидные производные
BG101118A (en) Therapeutical compounds
EP1024145A3 (en) Novel azalides and methods of making same
MA25009A1 (fr) Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes
YU41500A (sh) Novi makrolidi
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
MXPA04012965A (es) Inhibidores virales.
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
CY1111693T1 (el) Αντιιικοι παραγοντες
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
TR200102128T2 (tr) Ketolid antibiyotikler
NO996108L (no) 9-oksinerytromycinderivater
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
GT199900208A (es) Antibiòticos cetòlidos carbamato y carbazato.
BG106366A (en) Moxifloxacin formulation containing common salt
DE60208404D1 (de) Kreuzverquerte glycopeptid-cephalosporin-antibiotika
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
ITMI20021405A0 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato respiratorio